News & Views

May 6, 2024

Don’t Blame The Molecule, You May Be The Problem – Outsourced Pharma Chief Editor Interview

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

Louis Garguilo, Chief Editor, Outsourced Pharma has recently published an interview with Ali Pashazadeh, CEO of Treehill Partners, about drug development decision-making and...

August 4, 2026

The Medicine Maker – Ali Pashazadeh on the Bottlenecks Slowing Drug Development

Posted By: TreehillPartners
In: Drug Development, Financing & Capital Markets, Leadership & Restructuring

July 21, 2026

The Medicine Maker Power List 2026 – Treehill Partners CEO Named Among the Most Influential Voices in Biopharma

Posted By: TreehillPartners
In: Strategy & Corporate Development

July 1, 2026

The Real Questions Behind the GLP-1 Boom

Posted By: TreehillPartners
In: Business Development & Licensing, Drug Development

June 19, 2026

The Drug Development Sector Is Failing Patients – And It Is Time We Asked Why

Posted By: TreehillPartners
In: Drug Development

June 16, 2026

Is Pharma at its “Nokia Moment” – Why the Pushpin of Global Drug Development Is Moving East

Posted By: TreehillPartners
In: Drug Development, Leadership & Restructuring, Strategy & Corporate Development

March 11, 2024

Roundtable: Drug Pricing and Patient Cost

Posted By: TreehillPartners
In: Drug Development

The Gap Is Where The Pain Is: Drug Pricing and Patient Cost...

June 1, 2026

The Cost of Coming Second in Clinical Trials

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

May 12, 2026

The Hidden Risks Behind Biotech Layoffs

Posted By: TreehillPartners
In: Leadership & Restructuring

March 25, 2026

Will Biotech Still Be Relevant in 2030? – Treehill on Onyx Newsroom

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

March 24, 2026

Biotechs Must Face Reality to Succeed in Today’s Funding Environment – Treehill Partners CEO in Biospace

Posted By: TreehillPartners
In: Financing & Capital Markets, Strategy & Corporate Development

March 5, 2026

JPM 2026 and Biotech’s New Reality – Treehill Partners CEO in Pharmaphorum

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

January 16, 2024

Scrip Asks… What Does 2024 Hold For Biopharma? – Treehill Partners CEO Ali Pashazadeh featured in Scrip’s annual outlook

Posted By: TreehillPartners
In: Financing & Capital Markets

Going into 2024, Treehill expects an even greater degree of scrutiny by boards and investors on the merits of deploying capital from the dwindling cash reserves to conducting clinical studies...

February 23, 2026

Scrip Asks – What Does 2026 Hold For Biopharma

Posted By: TreehillPartners
In: Leadership & Restructuring

February 19, 2026

Riding the Gene Therapy Rollercoaster into 2026 – Treehill CEO in Inside Precision Medicine

Posted By: TreehillPartners
In: Drug Development

February 9, 2026

Treehill Partners Featured in Cell & Gene Therapy Review’s 2026 Industry Predictions

Posted By: TreehillPartners
In: Drug Development

January 22, 2026

Oncology Investment – Treehill in Mergermarket

Posted By: TreehillPartners
In: Dealmaking

January 19, 2026

Scrip Asks – What Does 2026 Hold For Biopharma – Part 2

Posted By: TreehillPartners
In: Dealmaking, Drug Development

January 16, 2024

What Does 2024 Hold For Biopharma? Treehill Partners featured in Scrip

Posted By: TreehillPartners
In: Uncategorized

Treehill Partners featured amongst prominent KOLs in Part 2 of Scrip's 2024 biopharma outlook interview, discussing funding environment, M&A, and partnering...

January 13, 2026

Clinical Trial Partners: Sink or Swim (JPM 2026 Series, Episode 2) – Treehill Partners on Onyx Newsroom

Posted By: TreehillPartners
In: Drug Development

January 9, 2026

Global Shifts And Strategic Resilience Will Shape CGT In 2026 – Treehill in Cell & Gene

Posted By: TreehillPartners
In: Drug Development

January 9, 2026

Scrip Asks – What does 2026 hold for Biopharma? Part 1

Posted By: TreehillPartners
In: Dealmaking

November 20, 2025

London Life Sciences Week – In-Depth Interview

Posted By: TreehillPartners
In: Drug Development

November 19, 2025

Manufacturing Flexibility

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

December 19, 2023

Development Success in a Troubling Economic Environment – Medicine Maker Interview

Posted By: TreehillPartners
In: Drug Development

November 14, 2025

Treehill Partners Featured in FirstWord ExpertViews: The Convergence of Pharma and Biotech

Posted By: TreehillPartners
In: Strategy & Corporate Development

November 3, 2025

Pharma’s Path Through Industry Turbulence

Posted By: TreehillPartners
In: Drug Development, Leadership & Restructuring

October 23, 2025

Neurology M&A – Treehill Quotes in Endpoints News

Posted By: TreehillPartners
In: Dealmaking

October 1, 2025

Treehill Partners CEO Featured in Newsweek Coverage of TrumpRx Initiative

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

September 30, 2025

Treehill Partners Experts Featured in FirstWord Report on Biomarkers in Rare Disease Therapies

Posted By: TreehillPartners
In: Drug Development, Leadership & Restructuring, Strategy & Corporate Development

Subscribe to our mailings!

Global Shifts And Strategic Resilience Will Shape CGT In 2026 – Treehill in Cell & Gene

As cell and gene therapy enters a pivotal year, Treehill Partners’ Founder Ali Pashazadeh joined Dr. Miguel Forte, CEO of Kiji Therapeutics and President of

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.